Malignant glioma

Lessons from genomics, mouse models, and stem cells

Jian Chen, Renée M. McKay, Luis F. Parada

Research output: Contribution to journalArticle

294 Citations (Scopus)

Abstract

Eighty percent of malignant tumors that develop in the central nervous system are malignant gliomas, which are essentially incurable. Here, we discuss how recent sequencing studies are identifying unexpected drivers of gliomagenesis, including mutations in isocitrate dehydrogenase 1 and the NF-κB pathway, and how genome-wide analyses are reshaping the classification schemes for tumors and enhancing prognostic value of molecular markers. We discuss the controversies surrounding glioma stem cells and explore how the integration of new molecular data allows for the generation of more informative animal models to advance our knowledge of glioma's origin, progression, and treatment.

Original languageEnglish (US)
Pages (from-to)36-47
Number of pages12
JournalCell
Volume149
Issue number1
DOIs
StatePublished - Mar 30 2012

Fingerprint

Genomics
Stem cells
Glioma
Tumors
Stem Cells
Isocitrate Dehydrogenase
Neurology
Animals
Genes
Neoplasms
Central Nervous System
Animal Models
Genome
Mutation

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Malignant glioma : Lessons from genomics, mouse models, and stem cells. / Chen, Jian; McKay, Renée M.; Parada, Luis F.

In: Cell, Vol. 149, No. 1, 30.03.2012, p. 36-47.

Research output: Contribution to journalArticle

Chen, Jian ; McKay, Renée M. ; Parada, Luis F. / Malignant glioma : Lessons from genomics, mouse models, and stem cells. In: Cell. 2012 ; Vol. 149, No. 1. pp. 36-47.
@article{d04de9f245b147c9a7192d82de5a8173,
title = "Malignant glioma: Lessons from genomics, mouse models, and stem cells",
abstract = "Eighty percent of malignant tumors that develop in the central nervous system are malignant gliomas, which are essentially incurable. Here, we discuss how recent sequencing studies are identifying unexpected drivers of gliomagenesis, including mutations in isocitrate dehydrogenase 1 and the NF-κB pathway, and how genome-wide analyses are reshaping the classification schemes for tumors and enhancing prognostic value of molecular markers. We discuss the controversies surrounding glioma stem cells and explore how the integration of new molecular data allows for the generation of more informative animal models to advance our knowledge of glioma's origin, progression, and treatment.",
author = "Jian Chen and McKay, {Ren{\'e}e M.} and Parada, {Luis F.}",
year = "2012",
month = "3",
day = "30",
doi = "10.1016/j.cell.2012.03.009",
language = "English (US)",
volume = "149",
pages = "36--47",
journal = "Cell",
issn = "0092-8674",
publisher = "Cell Press",
number = "1",

}

TY - JOUR

T1 - Malignant glioma

T2 - Lessons from genomics, mouse models, and stem cells

AU - Chen, Jian

AU - McKay, Renée M.

AU - Parada, Luis F.

PY - 2012/3/30

Y1 - 2012/3/30

N2 - Eighty percent of malignant tumors that develop in the central nervous system are malignant gliomas, which are essentially incurable. Here, we discuss how recent sequencing studies are identifying unexpected drivers of gliomagenesis, including mutations in isocitrate dehydrogenase 1 and the NF-κB pathway, and how genome-wide analyses are reshaping the classification schemes for tumors and enhancing prognostic value of molecular markers. We discuss the controversies surrounding glioma stem cells and explore how the integration of new molecular data allows for the generation of more informative animal models to advance our knowledge of glioma's origin, progression, and treatment.

AB - Eighty percent of malignant tumors that develop in the central nervous system are malignant gliomas, which are essentially incurable. Here, we discuss how recent sequencing studies are identifying unexpected drivers of gliomagenesis, including mutations in isocitrate dehydrogenase 1 and the NF-κB pathway, and how genome-wide analyses are reshaping the classification schemes for tumors and enhancing prognostic value of molecular markers. We discuss the controversies surrounding glioma stem cells and explore how the integration of new molecular data allows for the generation of more informative animal models to advance our knowledge of glioma's origin, progression, and treatment.

UR - http://www.scopus.com/inward/record.url?scp=84859183715&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859183715&partnerID=8YFLogxK

U2 - 10.1016/j.cell.2012.03.009

DO - 10.1016/j.cell.2012.03.009

M3 - Article

VL - 149

SP - 36

EP - 47

JO - Cell

JF - Cell

SN - 0092-8674

IS - 1

ER -